Images List Premium Download Classic

Cirrhosis

Cirrhosis-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Adeno-associated viral vectors for the gene therapy of metabolic diseases
Universitat Autonoma De Barcelona
October 12, 2017 - N°20170290926

The present invention discloses adeno-associated viral vectors useful in gene therapy methods for the treatment of obesity, insulin resistance, type 2 diabetes, liver cirrhosis and non-alcoholic fatty liver disease (nafld)/non-alcoholic steatohepatitis (nash). The invention also relates to polynucleotides, plasmids, vectors and methods for the production of such adeno-associated viral vectors. The invention also relates to pharmaceutical compositions comprising said vectors.
Pharmaceutical composition comprising gold-containing agent for preventing or treating liver fibrosis or liver cirrhosis
Korea United Pharm. Inc.
September 21, 2017 - N°20170266219

The present invention relates to a pharmaceutical composition for preventing or treating liver fibrosis or liver cirrhosis, and more specifically, to a pharmaceutical composition for preventing or treating liver fibrosis or liver cirrhosis comprising a gold-containing agent. The pharmaceutical composition of the present invention, by comprising the gold-containing agent as an active ingredient, not only promotes m2-type transformation of ...
Probiotic bifidobacterium adolescentis strains
Chr. Hansen A/s
September 07, 2017 - N°20170252382

The present invention relates to novel isolated strains of bifidobacterium adolescentis which are capable of i) increasing the trans-epithelial electrical resistance (ter) of a caco-2 cell monolayer after 10 h treatment to more than 120% of ter at treatment start, ii) inducing secretion of >200 pg/ml of il-10, and/or iii) inducing an il-10:il-12 ratio>1 when co-incubated ...
Cirrhosis Patent Pack
Download + patent application PDFs
Cirrhosis Patent Applications
Download + Cirrhosis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Cirrhosis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Novel compositions and methods useful for treating or preventing liver diseases or disorders, and promoting ...
Yale University
August 17, 2017 - N°20170232027

The invention includes a method of preventing or treating a toxic liver disease or disorder, such as but not limited to non-alcoholic steatohepatitis (nash), liver injury associated with or caused by alcohol consumption in a mammal afflicted with nash, alcoholic hepatitis, drug induced liver injury, primary sclerosing cholangitis, viral hepatitis, liver fibrosis, liver cirrhosis, and other toxic liver conditions, in ...
Sphinogosine-1-phosphate receptor modulators for treatment of cardiopulmonary disorders
The Scripps Research Institute
August 03, 2017 - N°20170217963

The invention provides compounds effective as sphingosine-1-phosphate receptor modulators for treatment of cardiopulmonary diseases, such as hypertension (including malignant hypertension), angina, myocardial infarction, cardiac arrhythmias, congestive heart failure, coronary heart disease, atherosclerosis, angina pectoris, dysrhythmias, cardiomyothopy (including hypertropic cardiomyothopy), heart failure, cardiac arrest, bronchitis, asthma, chronic obstructive pulmonary disease, cystic fibrosis, croup, emphysema, pleurisy, pulmonary fibrosis, pneumonia, pulmonary embolus, ...
Small molecule inhibitors of stat3 with anti-tumor activity
University Of Central Florida Research Foundation.
July 20, 2017 - N°20170202795

The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of stat3 signaling, stat3 dimerization, stat3-dna binding, stat5-dna binding, and/or aberrant cell growth in vitro or in vivo, e. G., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but ...
Cirrhosis Patent Pack
Download + patent application PDFs
Cirrhosis Patent Applications
Download + Cirrhosis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Cirrhosis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Pharmaceutical composition for preventing or treating of cirrhosis of liver comprising g protein coupled receptor 119 ...
Medizinische Hochschule Hannover
May 25, 2017 - N°20170143714

Provided is a pharmaceutical composition for preventing or treating liver fibrosis, comprising a gpr119 ligand as an active ingredient. The composition comprising the gpr119 ligand as an active ingredient significantly inhibits the expression of collagen i, transforming growth factor β (tgfβ) and α-smooth muscle actin (α-sma), thereby inhibiting hsc activation, and also significantly ...
Formulations of l-ornithine phenylacetate
Ocera Therapeutics, Inc.
May 18, 2017 - N°20170135973

Some embodiments of the present application are directed to oral formulations of l-ornithine phenylacetate and methods of using the same. These oral formulations offer alternative administration route than the standard intravenous administration of l-ornithine phenylacetate for treating hyperammonemia in patients having various acute and chronic liver diseases and disorders, for example, acute liver failure, liver cirrhosis, liver decompensation, portal hypertension, ...
Composition for preventing or treating fatty liver or insulin resistance syndrome including extracellular domain of ...
Industry-academic Cooperation Foundation, Yonsei University
May 04, 2017 - N°20170121380

The present invention relates to compositions and methods for treating fatty liver, steatohepatitis, or liver cirrhosis as well as insulin resistance and aging by administration of a dlk1-fc fusion protein constructed by conjugation of an extracellular domain of dlk1 or a fragment thereof with a human antibody fc region. Also provided are health functional foods containing a dlk1-fc ...
Urea compounds and their use as enzyme inhibitors
Industry-academic Cooperation Foundation, Yonsei University
April 13, 2017 - N°20170101381

Or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, parkinson's disease, levodopa-induced dyskinesia, huntington's disease, gilles de la tourette's syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, alzheimer's disease, epilepsy, ...
Treatment of the complications of chronic liver disease with caspase inhibitors
Conatus Pharmaceuticals, Inc.
April 13, 2017 - N°20170100448

Provided herein are methods and compositions for treatment of a portal hypertension and cirrhosis by administering a of a caspase inhibitor alone or in combination with current treatments for portal hypertension. Also provided are methods and compositions for reducing the progression of the clinical complications associated with portal hypertension by administering the caspase inhibitors described herein.
Novel composition for nonalcoholic fatty liver disease (nafld)
Cadila Healthcare Limited
March 30, 2017 - N°20170087127

The present invention provides a compound of formula (i) or pharmaceutical acceptable thereof, wherein ‘r’ is herein described. In addition, the invention relates to composition comprising effective therapeutic amount of compound of formula (i) and methods of using the compounds for treating or prevention disorder such as nonalcoholic fatty liver disease (nafld) including fatty liver (steatosis), nonalcoholic steatohepatitis (...
"methods for modeling hepatic inflammation"
University Of Pittsburgh - Of The Commonwealth System Of Higher Education
March 23, 2017 - N°20170083683

Provided herein are in silico methods of modeling hepatic inflammation, fibrosis/cirrhosis, and cancer. The models are computer-implemented agent-based models and are useful in determining patient prognoses in hepatic conditions, including viral infections, damage, inflammation, and cancer. The modeling system also is useful in modeling the effects of active agents on normal hepatic tissue or hepatic tissue perturbed by inflammation, ...
Cirrhosis Patent Pack
Download + patent application PDFs
Cirrhosis Patent Applications
Download + Cirrhosis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Cirrhosis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Pharmaceutical composition based on a hepatoprotector and prebiotic, and method for administrating
Centre Hospitalier Universitaire D'angers
March 16, 2017 - N°20170071968

The invention relates to medicine, hepatology and pharmacology and can be used for producing and using a pharmaceutical composition based on a hepatoprotector and a prebiotic for treating and preventing liver diseases which are caused by lipid-cholesterol exchange and selected from the following group: cholelitiasis mainly with cholesterol stones, alcoholic and non-alcoholic steatohepatitis, biliary cirrhosis, cholesterol imbibition gallbladder and drug-induced ...
Ultrapure tetrahydrocannabinol-11-oic-acids
Corbus Pharmaceuticals, Inc.
March 16, 2017 - N°20170071900

This application is in the field of medicinal chemistry and relates to ultrapure ajulemic acid, its synthesis, pharmaceutical compositions and methods of use thereof for the treatment and/or prevention of inflammation, pain, and fibrotic diseases including scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, idiopathic pulmonary fibrosis, dupuytren's contracture, keloids, chronic kidney disease, chronic graft ...
Ultrapure tetrahydrocannabinol-11-oic acids
Corbus Pharmaceuticals, Inc.
March 16, 2017 - N°20170071899

This application is in the field of medicinal chemistry and relates to ultrapure ajulemic acid, its synthesis, pharmaceutical compositions and methods of use thereof for the treatment and/or prevention of inflammation, pain, and fibrotic diseases including scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, idiopathic pulmonary fibrosis, dupuytren's contracture, keloids, chronic kidney disease, chronic graft ...
Ultrapure tetrahydrocannabinol-11-oic acids
Corbus Pharmaceuticals, Inc.
March 16, 2017 - N°20170071898

This application is in the field of medicinal chemistry and relates to ultrapure ajulemic acid, its synthesis, pharmaceutical compositions and methods of use thereof for the treatment and/or prevention of inflammation, pain, and fibrotic diseases including scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, idiopathic pulmonary fibrosis, dupuytren's contracture, keloids, chronic kidney disease, chronic graft ...
Compositions useful in treatment of ornithine transcarbamylase (otc) deficiency
The Trustees Of The University Of Pennsylvania
February 23, 2017 - N°20170051259

Viral vectors comprising engineered hotc dna and rna sequences are provided which when delivered to a subject in need thereof are useful for treating hyperammonemia, ornithine transcarbamylase transcarbamylase deficiency and symptoms associated therewith. Also provided are methods of using hotc for treatment of liver fibrosis cirrhosis in otcd patients by administering hotc.
Compositions useful in treatment of ornithine transcarbamylase (otc) deficiency
The Trustess Of The University Of Pennsylvania
January 26, 2017 - N°20170021037

Non-viral delivery systems comprising engineered hotc dna and rna sequences are provided which when delivered to a subject in need thereof are useful for treating hyperammonemia, ornithine transcarbamylase transcarbamylase deficiency and symptoms associated therewith. Also provided are methods of using hotc for treatment of liver fibrosis and/or cirrhosis in otcd patients by administering hotc.
Compositions and methods for treating renal failure
La Jolla Pharmaceutical Company
January 19, 2017 - N°20170014471

The present disclosure relates to the use of angiotensin ii in therapeutic methods for the treatment of renal failure, especially renal failure associated with cirrhosis.
Lysosomal acid lipase therapy for nafld and related diseases
Children's Hospital Medical Center
December 22, 2016 - N°20160367645

The present invention comprises methods and compositions for the treatment or alleviation of nafld (non-alcoholic fatty liver disease) and those conditions associated with nafld, including fatty liver disease, nonalcoholic steatohepatitis (nash) and cirrhosis through the use of pharmaceutical formulations of lysosomal acid lipase or related proteins and/or polypeptides. This invention is also directed to a combination therapy treatment for ...
Loading